News to Watch: Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences (NASDAQ:KIN) spotted trading -22.53% off 52-week high price. On the other end, the stock has been noted 58.05% away from the low price over the last 52-weeks. The stock changed 2.95% to recent value of $9.42. The stock transacted 190379 shares during last trading day however it has an average volume of 104.80K shares. The company has 39.23M of outstanding shares and 36.81M shares were floated in the market.

On Jan. 8, 2020, Kindred Biosciences (NASDAQ:KIN) a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, revealed that it has developed a technology to extend canine antibody half-life by up to three-fold. A patent application for this technology has been filed.

The study comprised 12 dogs, including four groups with various modifications incorporating KindredBio technology and one wild type canine antibody as control. Half-life extension was observed in all dogs across all groups other than the wild type, with the magnitude of extension over native antibody ranging from two to three-fold. Additional studies to further differentiate between lead molecules and expand sample size are planned for 2020.

Half-life extension technologies have the potential to improve therapeutic performance in numerous ways. Reduced dosing frequency and/or amount of dosing can lead to improved patient convenience and compliance. It can also substantially lower the cost of goods and enhance profitability and market positioning. In addition, higher drug concentration using the same dose and dosing interval as the parent antibody can result in extended drug exposure and potentially improved efficacy.

This innovation is a major breakthrough, with wide-ranging impact across our biologics portfolio, said KindredBio’s Chief Executive Officer, Richard Chin, M.D. Our market research shows that longer intervals between dosing is a critical driver of commercial success. This platform technology has the potential to significantly enhance the market positioning of KindredBio’s biologics pipeline through the creation of best-in-class and more profitable veterinary therapeutics, while also providing outlicensing opportunities.

Its earnings per share (EPS) expected to touch remained -30.20% for this year while earning per share for the next 5-years is expected to reach at 40.00%. KIN has a gross margin of 85.30%.

According to the most recent quarter its current ratio was 9.3 that represents company’s ability to meet its current financial obligations. The price moved ahead of 13.12% from the mean of 20 days, 15.55% from mean of 50 days SMA and performed 18.35% from mean of 200 days price. Company’s performance for the week was 11.08%, 21.71% for month and YTD performance remained 11.08%.

Leave a Reply

Your email address will not be published. Required fields are marked *